Omnichannel in European Pharma: Strategy Isn’t the Problem, Execution Is

Most European pharmaceutical organisations now have an omnichannel strategy in place and many are beginning to see results.

Yet a significant proportion are still falling behind. The issue isn’t ambition. It’s execution.

Omnichannel promises a seamless, insight-driven experience: coordinated field interactions, relevant digital engagement, personalised content, and connected follow-up, all aligned to healthcare professional (HCP) needs.

What many HCPs experience instead is fragmented outreach. Multichannel activity is not the same as true orchestration.

Why Omnichannel Execution Breaks Down

Across Europe, three structural challenges consistently limit progress.

1. Lack of a True Customer Backbone

• Without a unified customer view, omnichannel execution cannot scale.
• HCP data is often fragmented:
• CRM systems vary across affiliates
• Engagement data sits in disconnected platforms
• Consent and privacy requirements restrict data usability
• Analytics remain detached from frontline workflows

The result is inconsistent segmentation, limited personalisation, and orchestration that remains theoretical rather than actionable.

2. Fragmented Commercial Technology Stacks

Most pharma tech ecosystems have evolved organically rather than strategically.

Common challenges include:

• CRM platforms operating in isolation
• Marketing automation tools disconnected from field activity
• Analytics layered on top rather than embedded
• Content dispersed across teams and systems

This creates high operational effort with limited coordination and slows execution at scale.

3. Misaligned Operating Models

Even with strong leadership alignment, execution often remains siloed:

• Marketing drives campaigns
• Sales focuses on interactions
• Medical delivers education
• Market access manages stakeholders

True omnichannel requires shared ownership across functions, not parallel execution. Without this shift, orchestration cannot happen.

Why Europe Is the Ultimate Omnichannel Stress Test

Executing omnichannel in Europe is uniquely complex.

Key challenges include:

• Strict GDPR and consent requirements
• High affiliate autonomy across markets
• Variability in medical, legal and regulatory (MLR) processes
• Diverse languages, healthcare systems, and market dynamics

Scaling omnichannel in this environment means scaling governance, compliance, and localisation at the same time. This is where many global strategies stall.

What Leading Pharma Organisations Do Differently

The organisations successfully closing the execution gap focus on three core enablers.

1. CRM as Orchestration Infrastructure

Leading companies reposition CRM from a reporting tool to the central orchestration engine.

They integrate:

• Marketing automation
• Consent management
• Real-time analytics

AI-driven next-best-action insights are embedded directly into workflows, enabling field teams to act on data in real time.

2. Industrialised Content Operations

High-performing organisations move away from ad hoc content creation.

Instead, they build modular, scalable content systems:

• Global teams create compliant core assets
• Affiliates localise within structured frameworks
• Approval processes are streamlined

This reduces duplication, accelerates deployment, and ensures consistency across markets.

3. Centres of Excellence That Enable, Not Control

Effective Centres of Excellence act as accelerators, not gatekeepers.

They provide:

• Standardised playbooks
• Governance frameworks
• Shared analytics models
• Capability-building and training

This enables consistency at scale while preserving local agility.

Balancing Centralisation and Localisation

Execution leaders are deliberate in what they centralise versus localise.

They centralise:

• Data architecture
• Core technology platforms
• Analytics frameworks
• Governance standards

They localise:

• Messaging and content nuance
• Channel strategy
• Market-specific engagement priorities

This balance is intentional and critical to scaling successfully across Europe.

The Next Competitive Differentiator in Pharma Commercial Strategy

Within the next three years, omnichannel capability will be standard across European pharma. But only a minority will achieve:

• True cross-channel orchestration
• Measurable behavioural impact on HCP engagement
• Rapid, compliant rollout across affiliates
• AI-enabled decision-making embedded in daily workflows

Execution, not strategy, will separate leaders from laggards.

Omnichannel does not fail because the vision is flawed. It fails because it requires a fundamentally different operating model, one that integrates data, technology, governance, and cross-functional collaboration. In Europe, that model must be designed intentionally.